Methods and Compositions for Modulating Glycosylation

• US 20090325944A1
• Filed: 04/11/2007
• Published: 12/31/2009
• Est. Priority Date: 04/12/2006
• Status: Abandoned Application

• Current Assignee: President and Fellows of Harvard College (Harvard Corporation)
• Original Assignee: President and Fellows of Harvard College (Harvard Corporation)
• Inventors: Walker Kahne, Suzanne, Gross, Benjamin
• Application Number:
  US12/226,151
• Publication Number:
  US 20090325944A1
• Time in Patent Office: Days
• US Class Current: 514/227.2
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07D 215/36 Sulfur atoms C07D215/24 takes precedence
• CPC Class Codes: C07D 235/26 Oxygen atoms
• CPC Class Codes: C07D 239/60 Three or more oxygen or sulfur atoms
• CPC Class Codes: C07D 239/70 condensed with carbocyclic rings or ring systems
• CPC Class Codes: C07D 263/58 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• CPC Class Codes: C07D 277/00 Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
• CPC Class Codes: C07D 279/06 not condensed with other rings
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 409/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 409/14 containing three or more hetero rings
• CPC Class Codes: C07D 417/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 513/04 Ortho-condensed systems

Abstract

The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for treating glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such as insulin resistance, nephropathy, microvascular damage, and endothelial dysfunction. The invention also relates in part to assays that are useful for identifying and testing candidate compounds for modulating glycosylation of proteins.

Claims

1. An isolated compound set forth as compound 4, or a derivative, analog, or variant thereof;

compound 5, or a derivative, analog, or variant thereof;

compound 6, or a derivative, analog, or variant thereof;

compound 7, or a derivative, analog, or variant thereof;

compound 8, or a derivative, analog, or variant thereof;

compound 9, or a derivative, analog, or variant thereof;

compound 10, or a derivative, analog, or variant thereof;

compound 11, or a derivative, analog, or variant thereof;

compound 12, or a derivative, analog, or variant thereof;

compound 13, or a derivative, analog, or variant thereof;

or compound 14, or a derivative, analog, or variant thereof.

2. A composition comprising an isolated compound of claim 1 and a pharmaceutically acceptable carrier.

3. (canceled)

4. A method for treating an OGT-associated disease or condition in a subject, comprising:

administering to a subject in need of such treatment an effective amount of an OGT-inhibiting compound to treat the OGT-associated disease or condition.

5. The method of claim 4, wherein the OGT-inhibiting compound is the compound set forth as compound 4 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 5 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 6 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 7 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 8 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 9 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 10 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 11 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 12 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 13 or an analog, derivative, or variant thereof that inhibits OGT activity;

or compound 14 or an analog, derivative, or variant thereof that inhibits OGT activity.

16. The method of claim 4, wherein the subject is human.

17. The method of claim 4, wherein the OGT-inhibiting compound is linked to a targeting molecule.

18. The method of claim 4, wherein the OGT-inhibiting compound is administered prophylactically to a subject at risk of having a OGT-associated disease or disorder.

19. The method of claim 4, wherein the OGT-inhibiting compound is administered in combination with an additional drug for treating a OGT-associated disease or disorder.

20. The method of claim 4, wherein the OGT-associated disease or disorder is Alzheimer'"'"'s disease;

cancer;

diabetes mellitus, insulin resistance, or a complication of diabetes.

21. The method of claim 20, wherein the complication of diabetes is microvascular damage, insulin resistance, vascular damage, nephropathy, skin ulcers, circulatory damage, diabetic nephropathy, diabetic retinopathy, macro-vascular disease, micro-vascular disease, or diabetic neuropathy.

6-15. -15. (canceled)

22. A method of evaluating the effect of a candidate compound on OGT activity, comprising:

contacting OGT bound to a probe with a candidate compound and

determining the displacement of the probe from the OGT,

wherein the displacement of the probe from the OGT indicates that the candidate compound inhibits OGT activity.

23. The method of claim 22, wherein the probe is compound 2 or 3.

24. The method of claim 22, wherein the displacement of the probe from the OGT is determined using a method comprising detecting fluorescence polarization.

25-41. -41. (canceled)

42. A method for inhibiting OGT activity in a cell or tissue, comprising:

contacting the cell or tissue with an effective amount of an OGT-inhibiting compound to inhibit OGT activity in the cell, or tissue.

43. The method of claim 42, wherein the OGT-inhibiting compound is the compound set forth as compound 4 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 5 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 6 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 7 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 8 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 9 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 10 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 11 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 12 or an analog, derivative, or variant thereof that inhibits OGT activity;

compound 13 or an analog, derivative, or variant thereof that inhibits OGT activity;

or compound 14 or an analog, derivative, or variant thereof that inhibits OGT activity.

54. The method of claim 42, wherein the OGT-inhibiting compound is linked to a targeting molecule.

44-53. -53. (canceled)

55. An isolated nucleic acid molecule comprising the nucleotide sequence set forth as SEQ ID NO:

1.

56. An isolated protein encoded by the nucleotide sequence set forth as SEQ ID NO:

1.

57. An isolated polypeptide comprising the amino acid sequence set forth as SEQ ID NO:

2.

58. A method for confirming the effect of a candidate compound as an inhibitor of OGT activity, the method comprising,

(a) contacting a sample containing the candidate compound with

(i) an OGT substrate polypeptide,

(ii) a UDP-GlcNAc probe comprising detectably labeled GlcNAc, and

(iii) OGT;

and

(b) determining the amount of transfer of the labeled GlcNAc to the OGT substrate polypeptide in the sample, wherein a lower amount of GlcNAc transferred to the OGT substrate in the sample compared to a control amount of GlcNAc transfer to the OGT substrate confirms the effect of the candidate compound as an inhibitor of OGT activity.

59-68. -68. (canceled)